Healthy Sleep, Orexin System and Addiction

Main Article Content

Ana Clementina Equihua-Benítez
Fabio García-García

Abstract

Introduction: sleep disturbances are often reported in the context of depression, anxiety, and substance abuse disorder, observations that have strengthened the idea that there is an underlying link between them. Recently, the orexinergic system has been proposed as a possible common regulator, as orexinergic innervation reaches both sleep and wake-promoting centers and the mesolimbic pathway, potentially allowing orexinergic stimuli to promote wakefulness and addiction concurrently.


Objective: to describe the involvement of the orexinergic system in behaviors such as sleep and substance abuse disorders, and the therapeutical potential of orexin modulators for the treatment of such conditions.


Method: a search in scientific databases (PubMed, Scopus and Science Direct) was carried out for information regarding sleep, the orexinergic system, and substance abuse disorders. Information regarding clinical trials for orexin modulators was extracted from the clinicaltrials.gov website and the International Standard Randomized Controlled Trial Number (ISRCTN) registry. Results: experimental evidence suggests that orexinergic hyperactivity can lead to insomnia and increase drug-seeking behavior. Therefore, orexin modulators are being tested for their potential as aid in the treatment of substance abuse disorders with alcohol, nicotine, and opioids, leading the ongoing clinical trials.


Discussion and conclusions: substance abuse disorders are often accompanied by sleep disturbances, a relationship that has been proved to be a risk factor for relapse. In this regard, orexinergic antagonists reduce the activity of the orexinergic system in humans, increasing sleep quality and potentially reducing the intensity of withdrawal symptoms. Therefore, the orexinergic system could function as the proposed link between sleep and issues such as substance abuse, anxiety, and depression.

Keywords:
orexins ,  sleep ,  substance use disorders ,  DORAs ,  SORAs ,  orexin agonist
Published: Jun 26, 2024

Article Details

How to Cite
Equihua-Benítez, A. C., & García-García, F. (2024). Healthy Sleep, Orexin System and Addiction. Revista Internacional De Investigación En Adicciones, 10(1), 80–90. https://doi.org/10.28931/riiad.2024.1.09
Section
Review Articles

References

Adamantidis, A. R., Zhang, F., Aravanis, A. M., Deisseroth, K., & de Lecea, L. (2007). Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature, 450(7168), 420-424. https://doi.org/10.1038/nature06310

Alvaro, P. K., Roberts, R. M., & Harris, J. K. (2013). A Systematic Review Assessing Bidirectionality between Sleep Disturbances, Anxiety, and Depression. Sleep, 36(7), 1059-1068. https://doi.org/10.5665/sleep.2810

Andersen, M. L., & Tufik, S. (2015). Sleep and the Modern Society. Journal of Sleep Disorders & Therapy, 4(5), 1-2. https://doi.org/10.4172/2167-0277.1000e131

Aserinsky, E., & Kleitman, N. (2003). Regularly Occurring Periods of Eye Motility, and Concomitant Phenomena, During Sleep. The Journal of Neuropsychiatry and Clinical Neurosciences, 15(4), 454-455. https://doi.org/10.1176/jnp.15.4.454

Becker, H. C. (2008). Alcohol Dependence, Withdrawal, and Relapse. Alcohol Research & Health: the Journal of the National Institute on Alcohol Abuse and Alcoholism, 31(4), 348-361.

Bonnet, M. H., & Arand, D. L. (2018). Treatment of insomnia in adults. In R. Benca & A. F. Eichler (Eds.). UpToDate (pp. 1-35). UpToDate Inc. Retrieved from https://uptodatefree.ir/topic.htm?path=treatment-of-insomnia-in-adults

Borbély, A. A. (1982). A two process model of sleep regulation. Human Neurobiology, 1(3), 195-204. https://cdn2.hubspot.net/hubfs/6674255/Two-Process-Model-Sleep-Regulation.pdf

Borbély, A. A., Daan, S., Wirz-Justice, A., & Deboer, T. (2016). The two-process model of sleep regulation: a reappraisal. Journal of Sleep Research, 25(2), 131-143. https://doi.org/10.1111/jsr.12371

Brower, K. J. (2003). Insomnia, alcoholism and relapse. Sleep Medicine Reviews, 7(6), 523-539. https://doi.org/10.1016/S1087-0792(03)90005-0

Brower, K. J. (2015). Assessment and treatment of insomnia in adult patients with alcohol use disorders. Alcohol, 49(4), 417-427. https://doi.org/10.1016/j.alcohol.2014.12.003

Brown, M., & Guilleminault, C. (2011). A Review of Sodium Oxybate and Baclofen in the Treatment of Sleep Disorders. Current Pharmaceutical Design, 17(15), 1430-1435. https://doi.org/10.2174/138161211796197098

Chattu, V. K., Manzar, M. D., Kumary, S., Burman, D., Spence, D. W., & Pandi-Perumal, S. R. (2018). The Global Problem of Insufficient Sleep and Its Serious Public Health Implications. Healthcare, 7(1), 1. https://doi.org/10.3390/healthcare7010001

Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., Fitch, T. E., Nakazato, M., Hammer, R. E., Saper, C. B., & Yanagisawa, M. (1999). Narcolepsy in orexin Knockout Mice: molecular genetics of sleep regulation. Cell, 98(4), 437-451. https://doi.org/10.1016/S0092-8674(00)81973-X

Chieffi, S., Carotenuto, M., Monda, V., Valenzano, A., Villano, I., Precenzano, F., Tafuri, D., Salerno, M., Filippi, N., Nuccio, F., Ruberto, M., De Luca, V., Cipolloni, L., Cibelli, G., Mollica, M. P., Iacono, D., Nigro, E., Monda, M., Messina, G., & Messina, A. (2017). Orexin System: The Key for a Healthy Life. Frontiers in Physiology, 8, 357. https://doi.org/10.3389/fphys.2017.00357

Coleman, P. J., Gotter, A. L., Herring, W. J., Winrow, C. J., & Renger, J. J. (2017). The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia. Annual Review of Pharmacology and Toxicology, 57(1), 509-533. https://doi.org/10.1146/annurev-pharmtox-010716-104837

Coutrot, A., Lazar, A. S., Richards, M., Manley, E., Wiener, J. M., Dalton, R. C., Hornberger, M., & Spiers, H. J. (2022). Reported sleep duration reveals segmentation of the adult life-course into three phases. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-34624-8

Dauvilliers, Y., Mignot, E., del Río, R., Du, Y., Hanson, E., Inoue, Y., Kadali, H., Koundourakis, E., Meyer, S., Rogers, R., Scammell, T. E., Sheikh, S. I., Swick, T., Szakács, Z., von Rosenstiel, P., Wu, J., Zeitz, H., Murthy, N. V., Plazzi, G., & von Hehn, C. (2023). Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1. The New England Journal of Medicine, 389(4), 309-321. https://doi.org/10.1056/NEJMoa2301940

De La Herrán-Arita, A. K., Zomosa-Signoret, V. C., Millán-Aldaco, D. A., Palomero-Rivero, M., Guerra-Crespo, M., Drucker-Colín, R., & Vidaltamayo, R. (2011). Aspects of the narcolepsy-cataplexy syndrome in O/E3-null mutant mice. Neuroscience, 183, 134-143. https://doi.org/10.1016/j.neuroscience.2011.03.029

de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L. F., Gautvik, V. T., Bartlett, F. S., Frankel, W. N., van den Pol, A. N., Bloom, F. E., Gautvik, K. M., & Sutcliffe, J. G. (1998). The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proceedings of the National Academy of Sciences of the United States of America, 95(1), 322-327. https://doi.org/10.1073/pnas.95.1.322

De Luca, R., Nardone, S., Grace, K. P., Venner, A., Cristofolini, M., Bandaru, S. S., Sohn, L. T., Kong, D., Mochizuki, T., Viberti, B., Zhu, L., Zito, A., Scammell, T. E., Saper, C. B., Lowell, B. B., Fuller, P. M., & Arrigoni, E. (2022). Orexin neurons inhibit sleep to promote arousal. Nature Communications, 13(1), 4163. https://doi.org/10.1038/s41467-022-31591-y

Equihua-Benítez, A. C., Guzmán-Vásquez, K., & Drucker-Colín, R. (2017). Understanding sleep-wake mechanisms and drug discovery. Expert Opinion on Drug Discovery, 12(7), 643-657. https://doi.org/10.1080/17460441.2017.1329818

Flores-Ramirez, F. J., Illenberger, J. M., Pascasio, G. E., Matzeu, A., Mason, B. J., & Martin-Fardon, R. (2022). Alternative use of suvorexant (Belsomra®) for the prevention of alcohol drinking and seeking in rats with a history of alcohol dependence. Frontiers in Behavioral Neuroscience, 16, 1085882. https://doi.org/10.3389/fnbeh.2022.1085882

Fragale, J. E., James, M. H., Avila, J. A., Spaeth, A. M., Aurora, R. N., Langleben, D., & Aston-Jones, G. (2021). TheInsomnia-Addiction Positive Feedback Loop: Role of the Orexin System. Frontiers of Neurology and Neuroscience, 45, 117-127. https://doi.org/10.1159/000514965

Fujiki, N., Yoshida, Y., Ripley, B., Mignot, E. J., & Nishino, S. (2003). Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep, 26(8), 953-959. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14746374

Garcia, A. N., & Salloum, I. M. (2015). Polysomnographic sleep disturbances in nicotine, caffeine, alcohol, cocaine, opioid, and cannabis use: A focused review. The American Journal on Addictions, 24(7), 590-598. https://doi.org/10.1111/ajad.12291

Hale, L., Troxel, W., & Buysse, D. J. (2020). Sleep Health: An Opportunity for Public Health to Address Health Equity. Annual Review of Public Health, 41(1), 81-99. https://doi.org/10.1146/annurev-publhealth-040119-094412

Hara, J., Beuckmann, C. T., Nambu, T., Willie, J. T., Chemelli, R. M., Sinton, C. M., Sugiyama, F., Yagami, K., Goto, K., Yanagisawa, M., & Sakurai, T. (2001). Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron, 30(2), 345-354. https://doi.org/10.1016/s0896-6273(01)00293-8

Harris, G. C., Wimmer, M., & Aston-Jones, G. (2005). A role for lateral hypothalamic orexin neurons in reward seeking. Nature, 437, 556-559. https://doi.org/10.1038/nature04071

Hassani, O. K., Lee, M. G., & Jones, B. E. (2009). Melanin-concentrating hormone neurons discharge in a reciprocal manner to orexin neurons across the sleep-wake cycle. Proceedings of the National Academy of Sciences of the United States of America, 106(7), 2418-2422. https://doi.org/10.1073/pnas.0811400106

Herring, W. J., Snyder, E., Budd, K., Hutzelmann, J., Snavely, D., Liu, K., Lines, C., Roth, T., & Michelson, D. (2012). Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology, 79(23), 2265-2274. https://doi.org/10.1212/WNL.0b013e31827688ee

Hoever, P., Dorffner, G., Beneš, H., Penzel, T., Danker-Hopfe, H., Barbanoj, M. J., Pillar, G., Saletu, B., Polo, O., Kunz, D., Zeitlhofer, J., Berg, S., Partinen, M., Bassetti, C. L., Högl, B., Ebrahim, I. O., Holsboer-Trachsler, E., Bengtsson, H., Peker, Y., ... Dingemanse, J. (2012). Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial. Clinical Pharmacology & Therapeutics, 91(6), 975-985. https://doi.org/10.1038/clpt.2011.370

Huhn, A. S., Finan, P. H., Gamaldo, C. E., Hammond, A. S., Umbricht, A., Bergeria, C. L., Strain, E. C., & Dunn, K. E. (2022). Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Science Translational Medicine, 14(650), eabn8238. https://doi.org/10.1126/scitranslmed.abn8238

Iio, K., Hashimoto, K., Nagumo, Y., Amezawa, M., Hasegawa, T., Yamamoto, N., Kutsumura, N., Takeuchi, K., Ishikawa, Y., Yamamoto, H., Tokuda, A., Sato, T., Uchida, Y., Inoue, A., Tanimura, R., Yanagisawa, M., Nagase, H., & Saitoh, T. (2023). Design and Synthesis of Orexin 1 Receptor-Selective Agonists. Journal of Medicinal Chemistry, 66(8), 5453-5464. https://doi.org/10.1021/acs.jmedchem.2c01773

Inutsuka, A., & Yamanaka, A. (2013). The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in Endocrinology, 4, 18. https://doi.org/10.3389/fendo.2013.00018

Irukayama-Tomobe, Y., Ogawa, Y., Tominaga, H., Ishikawa, Y., Hosokawa, N., Ambai, S., Kawabe, Y., Uchida, S., Nakajima, R., Saitoh, T., Kanda, T., Vogt, K., Sakurai, T., Nagase, H., & Yanagisawa, M. (2017). Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proceedings of the National Academy of Sciences of the United States of America, 114(22), 5731-5736. https://doi.org/10.1073/pnas.1700499114

Jha, M. K. (2022). Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant. International Journal of Neuropsychopharmacology, 25(1), 85-88. https://doi.org/10.1093/ijnp/pyab078

Kaplan, R. M. (2011). The Mind Reader: the Forgotten Life of Hans Berger, Discoverer of the EEG. Australasian Psychiatry, 19(2), 168-169. https://doi.org/10.3109/10398562.2011.561495

Kosten, T. R., & George, T. P. (2002). The neurobiology of opioid dependence: implications for treatment. Science & Practice Perspectives, 1(1), 13-20. https://doi.org/10.1151/spp021113

Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P. J., Nishino, S., & Mignot, E. (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell, 98(3), 365-376. http://www.ncbi.nlm.nih.gov/pubmed/10458611

Lu, J., Sherman, D., Devor, M., & Saper, C. B. (2006). A putative flip-flop switch for control of REM sleep. Nature, 441(7093), 589-594. https://doi.org/10.1038/nature04767

Luppi, P.-H., & Fort, P. (2019). Sleep–wakephysiology. Handbook of Clinical Neurology, 160, 359-370. https://doi.org/10.1016/B978-0-444-64032-1.00023-0

Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., & Elmquist, J. K. (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. Journal of Comparative Neurology, 435(1), 6-25. https://doi.org/10.1002/cne.1190

Matzeu, A., & Martin-Fardon, R. (2022). Understanding the Role of Orexin Neuropeptides in Drug Addiction: Preclinical Studies and Translational Value. Frontiers in Behavioral Neuroscience, 15, 787595. https://doi.org/10.3389/fnbeh.2021.787595

Medic, G., Wille, M., & Hemels, M. E. (2017). Short- and long-term health consequences of sleep disruption. Nature and Science of Sleep, 9, 151-161. https://doi.org/10.2147/NSS.S134864

Mieda, M., Hasegawa, E., Kisanuki, Y. Y., Sinton, C. M., Yanagisawa, M., & Sakurai, T. (2011). Differential Roles of Orexin Receptor-1 and -2 in the Regulation of Non-REM and REM Sleep. The Journal of Neuroscience, 31(17), 6518-6526. https://doi.org/10.1523/JNEUROSCI.6506-10.2011

Mieda, M., Willie, J. T., Hara, J., Sinton, C. M., Sakurai, T., & Yanagisawa, M. (2004). Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proceedings of the National Academy of Sciences of the United States of America, 101(13), 4649-4654. https://doi.org/10.1073/pnas.0400590101

Mignot, E., Lammers, G. J., Ripley, B., Okun, M., Nevsimalova, S., Overeem, S., Vankova, J., Black, J., Harsh, J., Bassetti, C., Schrader, H., & Nishino, S. (2002). The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Archives of Neurology, 59(10), 1553-1562. https://doi.org/10.1001/archneur.59.10.1553

Moruzzi, G., & Magoun, H. W. (1949). Brain stem reticular formation and activation of the EEG. Electroencephalography and Clinical Neurophysiology, 1(4), 455-473. http://www.ncbi.nlm.nih.gov/pubmed/18421835

Nagahara, T., Saitoh, T., Kutsumura, N., Irukayama-Tomobe, Y., Ogawa, Y., Kuroda, D., Gouda, H., Kumagai, H., Fujii, H., Yanagisawa, M., & Nagase, H. (2015). Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. Journal of Medicinal Chemistry, 58(20), 7931-7937. https://doi.org/10.1021/acs.jmedchem.5b00988

Ohayon, M. M. (2011). Epidemiological Overview of sleep Disorders in the General Population. Sleep Medicine Research, 2(1), 1-9. https://doi.org/10.17241/smr.2011.2.1.1

Pantazis, C. B., James, M. H., O’Connor, S., Shin, N., & Aston-Jones, G. (2022). Orexin-1 receptor signaling in ventral tegmental area mediates cue-driven demand for cocaine. Neuropsychopharmacology, 47(3), 741-751. https://doi.org/10.1038/s41386-021-01173-5

Perrey, D. A., & Zhang, Y. (2020). Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Research, 1731, 145922. https://doi.org/10.1016/j.brainres.2018.08.025

Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 18(23), 9996-10015. https://doi.org/10.1523/jneurosci.18-23-09996.1998

Roehrs, T., & Roth, T. (2018). Insomnia as a path to alcoholism: tolerance development and dose escalation. Sleep, 41(8), zsy091. https://doi.org/10.1093/sleep/zsy091

Roncero, C., Grau-López, L., Díaz-Morán, S., Miquel, L., Martínez-Luna, N., & Casas, M. (2012). Evaluación de las alteraciones del sueño en pacientes drogodependientes hospitalizados. Medicina Clínica, 138(8), 332-335. https://doi.org/10.1016/j.medcli.2011.07.015

Saitoh, T., & Sakurai, T. (2023). The present and future of synthetic orexin receptor agonists. Peptides, 167, 171051. https://doi.org/10.1016/j.peptides.2023.171051

Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., Arch, J. R., Buckingham, R. E., Haynes, A. C., Carr, S. A., Annan, R. S., McNulty, D. E., Liu, W. S., Terrett, J. A., Elshourbagy, N. A., ... Yanagisawa, M. (1998). Orexins and orexin receptors: afamily of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell, 92(4), 573-585. https://doi.org/10.1016/s0092-8674(00)80949-6

Saper, C. B. (2013). The Neurobiology of Sleep. Continuum, 19(1), 19-31. https://doi.org/10.1212/01.CON.0000427215.07715.73

Saper, C. B., Chou, T. C., & Scammell, T. E. (2001). The sleep switch: hypothalamic control of sleep and wakefulness. Trends in Neurosciences, 24(12), 726-731. https://doi.org/10.1016/S0166-2236(00)02002-6

Sateia, M. J. (2014). International Classification of Sleep Disorders-Third Edition. Chest, 146(5), 1387-1394. https://doi.org/10.1378/chest.14-0970

Scammell, T. E. (2018). Clinical features and diagnosis of narcolepsy in adults. In R. Benca & A. F. Eichler (Eds.). UpToDate (pp. 1-22). Retrieved from https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-narcolepsy-in-adults?search=clinical features and diagnosis of narcolepsy&source=search_result&selectedTitle=1~81&usage_type=default&display_rank=1

Scott, A. J., Webb, T. L., Martyn-St James, M., Rowse, G., & Weich, S. (2021). Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials. Sleep Medicine Reviews, 60, 101556. https://doi.org/10.1016/j.smrv.2021.101556

Shaha, D. (2023). Insomnia Management: A Review and Update. The Journal of Family Practice, 72(6 Sup), S31-S36. https://doi.org/10.12788/jfp.0620

Siegel, J. (2004). Brain mechanisms that control sleep and waking. Naturwissenschaften, 91(8), 355-365. https://doi.org/10.1007/s00114-004-0541-9

Terrill, S. J., Hyde, K. M., Kay, K. E., Greene, H. E., Maske, C. B., Knierim, A. E., Davis, J. F., & Williams, D. L. (2016). Ventral tegmental area orexin 1 receptors promote palatable food intake and oppose postingestive negative feedback. American Journal of Physiology-regulatory Integrative and Comparative Physiology, 311(3), 592-599. https://doi.org/10.1152/ajpregu.00097.2016

Thannickal, T. C., John, J., Shan, L., Swaab, D. F., Wu, M.-F., Ramanathan, L., McGregor, R., Chew, K.-T., Cornford, M., Yamanaka, A., Inutsuka, A., Fronczek, R., Lammers, G. J., Worley, P. F., & Siegel, J. M. (2018). Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. Science Translational Medicine, 10(447), 1-14. https://doi.org/10.1126/scitranslmed.aao4953

Thannickal, T. C., Moore, R. Y., Nienhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M., Cornford, M., & Siegel, J. M. (2000). Reduced number of hypocretin neurons in human narcolepsy. Neuron, 27(3), 469-474. https://doi.org/10.1016/s0896-6273(00)00058-1

Tkachenko, O., Olson, E. A., Weber, M., Preer, L. A., Gogel, H., & Killgore, W. D. S. (2014). Sleep difficulties are associated with increased symptoms of psychopathology. Experimental Brain Research, 232(5), 1567-1574. https://doi.org/10.1007/s00221-014-3827-y

Uchiyama, M., Kambe, D., Imadera, Y., Kajiyama, Y., Ogo, H., & Uchimura, N. (2022). Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study. Psychopharmacology, 239(7), 2143-2154. https://doi.org/10.1007/s00213-022-06089-6

Watson, N. F., Badr, M. S., Belenky, G., Bliwise, D. L., Buxton, O. M., Buysse, D., Dinges, D. F., Gangwisch, J., Grandner, M. A., Kushida, C., Malhotra, R. K., Martin, J. L., Patel, S. R., Quan, S., & Tasali, E. (2015). Recommended Amount of Sleep for a Healthy Adult: A Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep, 38(6), 843-844. https://doi.org/10.5665/sleep.4716

Williams, J. T., Bolli, M. H., Brotschi, C., Sifferlen, T., Steiner, M. A., Treiber, A., Gatfield, J., & Boss, C. (2024). Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials. Journal of Medicinal Chemistry, 67(4), 2337-2348. https://doi.org/10.1021/acs.jmedchem.3c01894

Winrow, C. J., Tanis, K. Q., Reiss, D. R., Rigby, A. M., Uslaner, J. M., Uebele, V. N., Doran, S. M., Fox, S. V., Garson, S. L., Gotter, A. L., Levine, D. M., Roecker, A. J., Coleman, P. J., Koblan, K. S., & Renger, J. J. (2010). Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology, 58(1), 185-194. https://doi.org/10.1016/j.neuropharm.2009.07.008

Ye, H., Cao, T., Shu, Q., Chen, Y., Lu, Y., He, Z., & Li, Z. (2023). Blockade of orexin receptor 1 attenuates morphine protracted abstinence-induced anxiety-like behaviors in male mice. Psychoneuroendocrinology, 151, 106080. https://doi.org/10.1016/j.psyneuen.2023.106080

Yee, B., Chapman, J., Grunstein, R., Argent, C., D’Rozario, A., Hopkinson, C., Ramos, J., Landry, I., Yagoda, S., & Rege, B. (2023). O013 Preliminary Results from a Phase 1 Study of ALKS 2680, an Orexin-2 receptor Agonist, in Healthy Participants and Patients with Narcolepsy or Idiopathic Hypersomnia. Sleep Advances, 4(Sup 1), A5-A6. https://doi.org/10.1093/sleepadvances/zpad035.013

Zamanirad, F., Fattahi, M., Amirteymori, H., Mousavi, Z., & Haghparast, A. (2023). The role of orexin-1 receptors within the ventral tegmental area in the extinction and reinstatement of methamphetamine place preference. Behavioural Brain Research, 453, 114608. https://doi.org/10.1016/j.bbr.2023.114608

Zeitzer, J. M., Buckmaster, C. L., Parker, K. J., Hauck, C. M., Lyons, D. M., & Mignot, E. (2003). Circadian and Homeostatic Regulation of Hypocretin in a Primate Model: Implications for the Consolidation of Wakefulness. The Journal of Neuroscience, 23(8), 3555-3560. https://doi.org/10.1523/JNEUROSCI.23-08-03555.2003

Zhang, D., Perrey, D. A., Decker, A. M., Langston, T. L., Mavanji, V., Harris, D. L., Kotz, C. M., & Zhang, Y. (2021). Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists. Journal of Medicinal Chemistry, 64(12), 8806-8825. https://doi.org/10.1021/acs.jmedchem.1c00841